



ABX-PF1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF XIAO FENG

I, XIAO FENG, hereby declare that:

1. I am currently Scientist II at Abgenix, Inc. (hereinafter "Abgenix"), Assignee of the above-identified application.
2. Under my instruction and supervision, hybridoma clones 4.1.1 and 11.2.1, which are specifically identified in the specification of the above-identified application, were frozen and stored in Liquid Nitrogen Tank #2 at Abgenix.
3. On April 11, 2005, I retrieved clones 4.1.1 and 11.2.1 from our stored supply and forwarded them to Dr. Vahe Bedian at Pfizer Inc.

4. I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of a patent issuing from the above-identified application.

Date: September 1, 2005

Xiao Feng, Ph.D.: 



ABX-PF1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

Groton, Connecticut
September 1, 2005

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND DECLARATION OF VAHE BEDIAN

I, VAHE BEDIAN, hereby declare that:

1. I am a Senior Research Fellow in the Department of Exploratory Medicinal Sciences at Pfizer Inc (herein-after "Pfizer"), Assignee of the above-identified application.
2. Hybridoma clones PF1-4-1-1 and PF1-11-2-1 referred to in the August 8, 2005 American Type Culture Collection (ATCC) deposit certificate attached to applicants' Amendment Under 37 C.F.R. § 1.312, filed concurrently herewith, are identical to the hybridoma clones 4.1.1 and 11.2.1 specifically identified in the specification of the above-identified

application. The designations PF1-11-2-1 and PF1-4-1-1 on the ATCC certificate are synonymous with designations 11.2.1 and 4.1.1, respectively, which are used the application.


3. I received clones designated as clone 4.1.1 and clone 11.2.1 from Abgenix, Inc. Under my supervision, the clones were expanded and deposited at the ATCC on July 14, 2005.

4. I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of a patent issuing from the above-identified application.

Date: 9/8/05

Vahe Bedian, Ph.D.:



ABX-PF1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jessica H. Roark
Group Art Unit : 1644
Applicants : Hanson et al.
Application No. : 09/472,087 Conf. No.: 8298
Filed : December 23, 1999
Title : HUMAN MONOCLONAL ANTIBODIES TO
CTLA-4

MAILSTOP ISSUE FEE
Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

DECLARATION OF VAHE BEDIAN

I, Vahe Bedian, hereby declare that:

(1) I am a Research Advisor in the Immunology Department at Pfizer Inc. (herein-after "Pfizer"), Assignee of the above-identified application.

(2) Hybridoma cell lines PF1-4.1.1.1 and PF1-11.2.1.4 (herein-after "the subclones") referred to in the American Type Culture Collection (ATCC) deposit certificate attached to applicants' Amendment Under 37 C.F.R. § 1.312, filed concurrently herewith are identical to the hybridoma cell lines 4.1.1.1 and 11.2.1.4 specifically identified in the specification of the above application. The antibody

heavy and light chain cDNA sequences from subclones PF1-4.1.1.1 and PF1-11.2.1.4 were sequenced and compared to those of parent clones 4.1.1 and 11.2.1, respectively, which are disclosed in the figures of the above application. The cDNA sequence encoding the heavy chain (without the signal peptide sequence) from hybridoma cell line PF1-4.1.1.1 is identical to the corresponding sequence in SEQ ID NO: 53. The cDNA sequence encoding the light chain (without the signal peptide sequence) from hybridoma cell line PF1-4.1.1.1 is identical to the corresponding sequence in SEQ ID NO: 56. The cDNA sequence encoding the heavy chain (without the signal peptide sequence) from hybridoma cell line PF1-11.2.1.4 is identical to the corresponding sequence in SEQ ID NO: 61. The cDNA sequence encoding the light chain (without the signal peptide sequence) from hybridoma cell line PF1-11.2.1.4 is identical to the corresponding sequence in SEQ ID NO: 62.

(3) The subclones were froze and stored at the Bioprocess department at Pfizer according to Pfizer's usual business practice. Dr. Douglas C. Hansen, a named inventor in the above application, retrieved the subclones from the stored supply on April 15, 2003 and provided them to me. Under my supervision, the subclones were expanded and deposited at the ATCC on April 29, 2003.

(4) I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of a patent issuing from the above-identified application.

Date:

July 3, 2003

Vahe Badian
Vahe Badian



AMERICAN TYPE CULTURE COLLECTION

10801 University Blvd.
Manassas, VA 20110-2209
Telephone: 703-365-2700
Fax: 703-365-2745

FACSIMILE

Date: August 8, 2005

To: Dr. Ing-Kae Wang
Pfizer

Fax Number: 860-441-1154

From: ATCC Patent Depository **Number of pages:** 1 (Including this page)

REFERENCE: Patent Deposit

Description:

Mouse hybridoma cell line (PF1-4-1-1): LN 15918 assigned ATCC No. PTA-6862 and
Mouse hybridoma cell line (PF1-11-2-1): LN 15919 assigned ATCC No. PTA-6863.

Date of Deposit: July 14, 2005. The ATCC Certificate of Deposit will be forwarded to you within 30 days. The following fees will be invoiced:

Total fees for PTA-6862 and PTA-6863 \$5,000.00
(storage/informing/viability testing)


Tanya Nunnally, Patent Specialist
ATCC Patent Depository

ATCC



10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-365-2745

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.

To: (Name and Address of Depositor or Attorney)

Pfizer, Inc.
Attn: Dr. L. H. Huang
Global Research & Development
Groton Laboratories
Eastern Point Road
Groton, CT 06340

Deposited on Behalf of: Pfizer Inc.

Identification Reference by Depositor:

Mouse Hybridoma Cell Line (PF1-4.1.1.1): LN 15887
Mouse Hybridoma Cell Line (PF1-4.13.1.1): LN 15888
Mouse Hybridoma Cell Line (PF1-6.1.1.3): LN 15889
Mouse Hybridoma Cell Line (PF1-11.2.1.4): LN 15890

Patent Deposit Designation

PTA-5166
PTA-5167
PTA-5168
PTA-5169

The deposits were accompanied by: a scientific description, a proposed taxonomic description indicated above. The deposits were received April 29, 2003 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: X We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested May 19, 2003. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:

Marie Harris
Marie Harris, Patent Specialist, ATCC Patent Depository

Date: June 4, 2003

cc: Li Su

Ref: Docket or Case No.: PC10508A